Cargando…

Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report

A fetal autoimmune-mediated atrioventricular block is a passively acquired autoimmune disease in which maternal autoantibodies enter the fetal circulation via the placenta and subsequently cause inflammation and fibrosis of the atrioventricular node. Once fetal autoimmune-mediated atrioventricular b...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Li, Zhou, Yan, Wang, Chuan, Li, Yifei, Zhu, Qi, Hua, Yimin, Qiao, Lina, Wu, Jinlin, Zhou, Kaiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636095/
https://www.ncbi.nlm.nih.gov/pubmed/34869674
http://dx.doi.org/10.3389/fcvm.2021.759260
_version_ 1784608464643817472
author Zhao, Li
Zhou, Yan
Wang, Chuan
Li, Yifei
Zhu, Qi
Hua, Yimin
Qiao, Lina
Wu, Jinlin
Zhou, Kaiyu
author_facet Zhao, Li
Zhou, Yan
Wang, Chuan
Li, Yifei
Zhu, Qi
Hua, Yimin
Qiao, Lina
Wu, Jinlin
Zhou, Kaiyu
author_sort Zhao, Li
collection PubMed
description A fetal autoimmune-mediated atrioventricular block is a passively acquired autoimmune disease in which maternal autoantibodies enter the fetal circulation via the placenta and subsequently cause inflammation and fibrosis of the atrioventricular node. Once fetal autoimmune-mediated atrioventricular block occurs, it only takes a short time to progress from first-degree atrioventricular block to complete atrioventricular block, meaning that the damage is often irreversible. Autoimmune—associated AVB, a rare but life—threatening disorder, occurs in 2–5% of pregnancies with positive anti—Ro/SSA (the most common one) and La/SSB antibodies. The perinatal mortality of neonates with AVB outlined in research is approximately 30%. Thus far, for autoimmune-associated AVB fetuses, currently used treatments include corticosteroids, hydroxychloroquine, intravenous immunoglobulin (IVIG), b—sympathomimetic agent, and even plasma exchange. Currently, approaches for preventing the progression and recurrence of a fetal atrioventricular block are still controversial. Here, we reported a baby of successful prevention from the fate of the fetal atrioventricular block by adopting prophylactic comprehensive prenatal therapy.
format Online
Article
Text
id pubmed-8636095
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86360952021-12-02 Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report Zhao, Li Zhou, Yan Wang, Chuan Li, Yifei Zhu, Qi Hua, Yimin Qiao, Lina Wu, Jinlin Zhou, Kaiyu Front Cardiovasc Med Cardiovascular Medicine A fetal autoimmune-mediated atrioventricular block is a passively acquired autoimmune disease in which maternal autoantibodies enter the fetal circulation via the placenta and subsequently cause inflammation and fibrosis of the atrioventricular node. Once fetal autoimmune-mediated atrioventricular block occurs, it only takes a short time to progress from first-degree atrioventricular block to complete atrioventricular block, meaning that the damage is often irreversible. Autoimmune—associated AVB, a rare but life—threatening disorder, occurs in 2–5% of pregnancies with positive anti—Ro/SSA (the most common one) and La/SSB antibodies. The perinatal mortality of neonates with AVB outlined in research is approximately 30%. Thus far, for autoimmune-associated AVB fetuses, currently used treatments include corticosteroids, hydroxychloroquine, intravenous immunoglobulin (IVIG), b—sympathomimetic agent, and even plasma exchange. Currently, approaches for preventing the progression and recurrence of a fetal atrioventricular block are still controversial. Here, we reported a baby of successful prevention from the fate of the fetal atrioventricular block by adopting prophylactic comprehensive prenatal therapy. Frontiers Media S.A. 2021-11-12 /pmc/articles/PMC8636095/ /pubmed/34869674 http://dx.doi.org/10.3389/fcvm.2021.759260 Text en Copyright © 2021 Zhao, Zhou, Wang, Li, Zhu, Hua, Qiao, Wu and Zhou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Zhao, Li
Zhou, Yan
Wang, Chuan
Li, Yifei
Zhu, Qi
Hua, Yimin
Qiao, Lina
Wu, Jinlin
Zhou, Kaiyu
Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report
title Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report
title_full Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report
title_fullStr Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report
title_full_unstemmed Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report
title_short Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report
title_sort successful prevention of fetal autoimmune-mediated heart block by combined therapies with hydroxychloroquine and intravenous immunoglobulin: a case report
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636095/
https://www.ncbi.nlm.nih.gov/pubmed/34869674
http://dx.doi.org/10.3389/fcvm.2021.759260
work_keys_str_mv AT zhaoli successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport
AT zhouyan successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport
AT wangchuan successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport
AT liyifei successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport
AT zhuqi successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport
AT huayimin successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport
AT qiaolina successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport
AT wujinlin successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport
AT zhoukaiyu successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport